Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma

Blood

Volumn 116, Issue 12, 2010, Pages 2033-2039

  Gabriel, Ian H ^a   Sergeant, Ruhena ^b   Szydlo, Richard ^a   Apperley, Jane F ^a   DeLavallade, Hugues ^a   Alsuliman, Abdullah ^a   Khoder, Ahmad ^a   Marin, David ^a   Kanfer, Edward ^a   Cooper, Nichola ^a   Davis, John ^a   MacDonald, Donald ^a   Bua, Marco ^a   Foroni, Letizia ^a   Giles, Chrissy ^a   Milojkovic, Dragana ^a   Rahemtulla, Amin ^a   Rezvani, Katayoun ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER GENETICS; CANCER REGRESSION; CANCER SURVIVAL; FEMALE; GENE; GENE INTERACTION; HLA BW4 GENE; HUMAN; IMMUNOGENETICS; KIR3DS1 GENE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; AUTOTRANSPLANTATION; DISEASE FREE SURVIVAL; GENETICS; IMMUNOLOGY; MIDDLE AGED; MORTALITY; NATURAL KILLER CELL; PREDICTIVE VALUE; PROGNOSIS; STEM CELL TRANSPLANTATION;

HLA B ANTIGEN; HLA-BW4 ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DS1;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; HLA-B ANTIGENS; HUMANS; IMMUNOGENETICS; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, KIR3DS1; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 77957193432     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-03-273706     Document Type: Article

References (48)

1. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335(2):91-97. (Pubitemid 26240110)
2. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348(19):1875-1883. (Pubitemid 36532313)
3. Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood. 2004;104(10):3052-3057. (Pubitemid 39507119)
4. Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood. 2005;106(1):35-39. (Pubitemid 40967171)
5. Lokhorst HM, Schmidt-Wolf I, Sonneveld P, et al. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica. 2008;93(1):124-127.
6. Rajkumar SV, Rosinol L, Hussein M, et al. Multi-center, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol. 2008;26(13):2171-217.
7. Roccaro AM, Vacca A, Ribatti D. Bortezomib in the treatment of cancer. Recent Pat Anticancer Drug Discov. 2006;1(3):397-403.
8. Stewart AK, Richardson PG, San-Miguel JF. How I treat multiple myeloma in younger patients. Blood. 2009;114(27):5436-5443.
9. Attal M, Harousseau JL. The role of high-dose therapy with autologous stem cell support in the era of novel agents. Semin Hematol. 2009;46(2):127-132.
10. Bensinger WI. Role of autologous and allogeneic stem cell transplantation in myeloma. Leukemia. 2009;23(3):442-448.
11. Lokhorst HM, Wu K, Verdonck LF, et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood. 2004;103(11):4362-4364. (Pubitemid 38685385)
12. Perez-Simon JA, Caballero D, Mateos MV, San Miguel JF. Graft vs. host disease and graft vs. myeloma effect after non-myeloablative allogeneic transplantation. Leuk Lymphoma. 2004;45(9):1725-1729. (Pubitemid 38997137)
13. Crawley C, Iacobelli S, Bjorkstrand B, Apperley JF, Niederwieser D, Gahrton G. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood. 2007;109(8):3588-3594. (Pubitemid 46572554)
14. Gahrton G, Svensson H, Cavo M, et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol. 2001;113(1):209-216.
15. Costa LJ, Kumar S, Dispenzieri A, et al. Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Leuk Lymphoma. 2009;50(5):781-787.
16. Bensinger WI, Buckner CD, Anasetti C, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood. 1996;88(7):2787-2793. (Pubitemid 26327535)
17. Caligiuri MA. Human natural killer cells. Blood. 2008;112(3):461-469.
18. Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225-274.
19. Vivier E, Nunes JA, Vely F. Natural killer cell signaling pathways. Science. 2004;306(5701):1517-1519. (Pubitemid 39564941)
20. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol. 2005;5(3):201-214. (Pubitemid 40364822)
21. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097-2100. (Pubitemid 34229476)
22. Clausen J, Wolf D, Petzer AL, et al. Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation. Clin Exp Immunol. 2007;148(3):520-528.
23. Giebel S, Locatelli F, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003;102(3):814-819.
24. Miller JS, Cooley S, Parham P, et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood. 2007;109(11):5058-5061. (Pubitemid 46827806)
25. Alici E, Sutlu T, Bjorkstrand B, et al. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood. 2008;111(6):3155-3162.
26. Shi J, Tricot G, Szmania S, et al. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol. 2008;143(5):641-653.
27. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-1473.
28. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102(5):1115-1123.
29. Cooley S, Trachtenberg E, Bergemann TL, et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood. 2009;113(3):726-732.
30. Savani BN, Rezvani K, Mielke S, et al. Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood. 2006;107(4):1688-1695. (Pubitemid 43242410)
31. Martin MP, Gao X, Lee JH, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet. 2002;31(4):429-434. (Pubitemid 35154456)
32. Kroger N, Binder T, Zabelina T, et al. Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation. Transplantation. 2006;82(8):1024-1030. (Pubitemid 44632116)
33. Alter G, Rihn S, Walter K, et al. HLA class I subtype-dependent expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute human immunodeficiency virus type 1 infection. J Virol. 2009;83(13):6798-6805.
34. Lopez-Vazquez A, Rodrigo L, Martinez-Borra J, et al. Protective effect of the HLA-Bw4I80 epitope and the killer cell immunoglobulin-like receptor 3DS1 gene against the development of hepatocellular carcinoma in patients with hepatitis C virus infection. J Infect Dis. 2005;192(1):162-165.
35. Carrington M, Wang S, Martin MP, et al. Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J Exp Med. 2005;201(7):1069-1075.
36. Butsch Kovacic M, Martin M, Gao X, et al. Variation of the killer cell immunoglobulin-like receptors and HLA-C genes in nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2005;14(11 Pt 1):2673-2677.
37. Leung W, Handgretinger R, Iyengar R, Turner V, Holladay MS, Hale GA. Inhibitory KIR-HLA receptor-ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma. Br J Cancer. 2007;97(4):539-542.
38. Venstrom JM, Zheng J, Noor N, et al. KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Cancer Res. 2009;15(23):7330-7334.
39. Stern M, Paulussen M, Rischewski J, Tichelli A, Gratwohl A. Missing ligand model in autologous stem cell transplantation. Br J Cancer. 2008;98(4):852-853.
40. Lee SH, Kim KS, Fodil-Cornu N, Vidal SM, Biron CA. Activating receptors promote NK cell expansion for maintenance, IL-10 production, and CD8 T cell regulation during viral infection. J Exp Med. 2009;206(10):2235-2251.
41. Ghio M, Contini P, Negrini S, Boero S, Musso A, Poggi A. Soluble HLA-I-mediated secretion of TGF-beta1 by human NK cells and consequent down-regulation of anti-tumor cytolytic activity. Eur J Immunol. 2009;39(12):3459-3468.
42. Bettini M, Vignali DA. Regulatory T cells and inhibitory cytokines in autoimmunity. Curr Opin Immunol. 2009;21(6):612-618.
43. Klein B, Tarte K, Jourdan M, et al. Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol. 2003;78(2):106-113.
44. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med. 2001;194(5):629-644.
45. Anagnostopoulos A, Evangelopoulou A, Sotou D, Gika D, Mitsibounas D, Dimopoulos MA. Incidence and evolution of monoclonal gammopathy of undetermined significance (MGUS) in Greece. Ann Hematol. 2002;81(7):357-361. (Pubitemid 36067639)
46. Venstrom JM, Gooley TA, Spellman S, et al. Donor activating KIR3DS1 is associated with decreased acute GvHD in unrelated allogeneic hematopoietic stem cell transplantation. Blood. 2010;115(15):3162-3165).
47. Chan HW, Miller JS, Moore MB, Lutz CT. Epigenetic control of highly homologous killer Ig-like receptor gene alleles. J Immunol. 2005;175(9):5966- 5974.
48. Bashirova AA, Martin MP, McVicar DW, Carrington M. The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense. Annu Rev Genomics Hum Genet. 2006;7:277-300. (Pubitemid 44627931)